AR059978A1 - Composiciones farmaceuticas - Google Patents
Composiciones farmaceuticasInfo
- Publication number
- AR059978A1 AR059978A1 ARP070101120A ARP070101120A AR059978A1 AR 059978 A1 AR059978 A1 AR 059978A1 AR P070101120 A ARP070101120 A AR P070101120A AR P070101120 A ARP070101120 A AR P070101120A AR 059978 A1 AR059978 A1 AR 059978A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- formulations
- forms
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Formas y formulaciones de VX-950 y sus usos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78442806P | 2006-03-20 | 2006-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059978A1 true AR059978A1 (es) | 2008-05-14 |
Family
ID=38523221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101120A AR059978A1 (es) | 2006-03-20 | 2007-03-20 | Composiciones farmaceuticas |
Country Status (11)
Country | Link |
---|---|
US (4) | US20070218138A1 (es) |
EP (1) | EP2001498A4 (es) |
JP (1) | JP2009530415A (es) |
CN (1) | CN101494979A (es) |
AR (1) | AR059978A1 (es) |
AU (1) | AU2007226983A1 (es) |
CA (1) | CA2645566A1 (es) |
PE (2) | PE20080123A1 (es) |
TW (1) | TW200812611A (es) |
UY (1) | UY30226A1 (es) |
WO (1) | WO2007109604A2 (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN183120B (es) | 1996-10-18 | 1999-09-11 | Vertex Pharma | |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
EP1893612B1 (en) * | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
EP1993994A2 (en) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
DK2007756T3 (en) | 2006-04-07 | 2015-10-05 | Vertex Pharma | MODULATORS OF ATP BINDING CASSETTE TRANSPORT |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
EA200970806A1 (ru) | 2007-02-27 | 2010-08-30 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
CA2679426A1 (en) | 2007-02-27 | 2008-09-04 | Luc Farmer | Inhibitors of serine proteases |
NZ582772A (en) | 2007-07-17 | 2012-06-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
EP2436682A1 (en) | 2007-08-30 | 2012-04-04 | Vertex Pharmceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
AU2009223014A1 (en) * | 2008-03-11 | 2009-09-17 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
MX2010010214A (es) | 2008-03-20 | 2010-12-21 | Virun Inc | Derivados de vitamina e y sus usos. |
CN102036572A (zh) | 2008-03-20 | 2011-04-27 | 维尔恩公司 | 包含生育酚的peg衍生物的乳剂 |
WO2009150194A1 (en) * | 2008-06-10 | 2009-12-17 | Janssen Pharmaceutica Nv | Telaprevir dosing regimen |
GB0815852D0 (en) | 2008-09-01 | 2008-10-08 | Unilever Plc | Improvements relating to pharmaceutical compositions |
US20110189297A1 (en) * | 2008-09-16 | 2011-08-04 | Sequicia Pharmaceuticals | Stable solid oral dosage co-formulations |
EP2396028A2 (en) | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
SG173178A1 (en) | 2009-04-03 | 2011-09-29 | Hoffmann La Roche | Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
WO2011014882A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
CA2780190C (en) | 2009-11-06 | 2020-05-05 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CA2788348A1 (en) | 2010-01-29 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Therapies for treating hepatitis c virus infection |
KR101622441B1 (ko) | 2010-03-23 | 2016-05-18 | 버런, 아이엔씨. | 자당 지방산 에스테르를 포함하는 나노에멀전 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
NZ602665A (en) * | 2010-03-25 | 2014-10-31 | Vertex Pharma | Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
KR20190061096A (ko) | 2010-04-22 | 2019-06-04 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
EP2581084A4 (en) * | 2010-05-31 | 2014-06-25 | Astellas Pharma Inc | SOLID DISPERSION COMPRISING A TRIAZOLE COMPOUND |
US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
US20120014912A1 (en) | 2010-07-14 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | Palatable pharmaceutical composition |
EP2630499A2 (en) | 2010-10-21 | 2013-08-28 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2012109646A1 (en) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Treatment of hcv in hiv infection patients |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
WO2012129099A1 (en) * | 2011-03-18 | 2012-09-27 | Abbott Laboratories | Formulations of phenyl uracil compounds |
EP2729145A4 (en) * | 2011-07-07 | 2014-12-10 | Arqule Inc | PYRROLOCHINOLINYLPYRROLIDIN-2,5-DION FORMULATIONS AND METHOD FOR THEIR PREPARATION AND USE |
EP2578974A1 (en) | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Process line for the production of freeze-dried particles |
DK2583677T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8809265B2 (en) | 2011-10-21 | 2014-08-19 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CN104010631B (zh) * | 2011-12-29 | 2016-08-17 | 艾伯维公司 | 包含hcv抑制剂的固体组合物 |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US20130195797A1 (en) | 2012-01-31 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
EP2811847B1 (en) | 2012-02-10 | 2017-12-13 | Virun, Inc. | Beverage compositions containing non-polar compounds |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
KR20220093389A (ko) | 2012-06-04 | 2022-07-05 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
WO2014015217A1 (en) | 2012-07-19 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
EP2935245A1 (en) * | 2012-12-21 | 2015-10-28 | Sandoz AG | Novel forms of telaprevir |
EA029081B9 (ru) | 2013-01-31 | 2018-09-28 | Джилид Фармассет Ллс | Комбинированный состав двух противовирусных соединений |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
CN105228593B (zh) | 2013-03-15 | 2018-08-28 | 勃林格殷格翰国际有限公司 | 呈无定形状态的hcv抑制剂的固体口服剂型 |
SI3650014T1 (sl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
CN113209024A (zh) * | 2013-12-31 | 2021-08-06 | 阿森迪亚制药有限责任公司 | 疏水性化合物的药物组合物 |
RS64400B1 (sr) | 2014-04-15 | 2023-08-31 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze |
KR20170033358A (ko) * | 2014-08-07 | 2017-03-24 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나아제 저해제의 신규한 제제 |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
CN106620711B (zh) * | 2015-11-03 | 2019-06-25 | 中国科学院大连化学物理研究所 | 一种含有白藜芦醇的组合物及其制备方法 |
JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
WO2017196712A1 (en) * | 2016-05-09 | 2017-11-16 | Dispersol Technologies, Llc | Improved drug formulations |
PL3518924T3 (pl) | 2016-09-30 | 2023-01-09 | Salix Pharmaceuticals, Inc. | Postacie stałej dyspersji ryfaksyminy |
WO2019134971A1 (en) * | 2018-01-04 | 2019-07-11 | Sandoz Ag | Encapsulated particles comprising a pharmaceutically active ingredient |
JP7489370B2 (ja) | 2019-03-04 | 2024-05-23 | 日本たばこ産業株式会社 | ピラゾール-アミド化合物の非晶質固体分散体 |
WO2021041348A1 (en) * | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
UY26615A1 (es) * | 2000-03-16 | 2001-10-25 | Pfizer Prod Inc | Inhibidor de la glucogeno fosforilasa. |
GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
WO2005043118A2 (en) * | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
SI1677827T1 (sl) * | 2003-10-27 | 2009-06-30 | Vertex Pharma | Zdravilni sestavek proti virusu hepatitisa c (hcv) |
CA2569310A1 (en) * | 2004-06-08 | 2005-12-29 | Maura Murphy | Pharmaceutical compositions |
-
2007
- 2007-03-19 WO PCT/US2007/064293 patent/WO2007109604A2/en active Application Filing
- 2007-03-19 JP JP2009501678A patent/JP2009530415A/ja active Pending
- 2007-03-19 US US11/687,716 patent/US20070218138A1/en not_active Abandoned
- 2007-03-19 TW TW096109379A patent/TW200812611A/zh unknown
- 2007-03-19 AU AU2007226983A patent/AU2007226983A1/en not_active Abandoned
- 2007-03-19 EP EP07758805A patent/EP2001498A4/en not_active Withdrawn
- 2007-03-19 CA CA002645566A patent/CA2645566A1/en not_active Abandoned
- 2007-03-19 CN CNA2007800171770A patent/CN101494979A/zh active Pending
- 2007-03-20 PE PE2007000305A patent/PE20080123A1/es not_active Application Discontinuation
- 2007-03-20 AR ARP070101120A patent/AR059978A1/es not_active Application Discontinuation
- 2007-03-20 PE PE2011000165A patent/PE20110286A1/es not_active Application Discontinuation
- 2007-03-20 UY UY30226A patent/UY30226A1/es unknown
-
2010
- 2010-04-26 US US12/767,409 patent/US20100267744A1/en not_active Abandoned
-
2011
- 2011-12-13 US US13/324,338 patent/US20120083441A1/en not_active Abandoned
-
2012
- 2012-07-10 US US13/545,562 patent/US20130079289A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100267744A1 (en) | 2010-10-21 |
TW200812611A (en) | 2008-03-16 |
US20070218138A1 (en) | 2007-09-20 |
EP2001498A2 (en) | 2008-12-17 |
PE20110286A1 (es) | 2011-05-21 |
US20120083441A1 (en) | 2012-04-05 |
CN101494979A (zh) | 2009-07-29 |
US20130079289A1 (en) | 2013-03-28 |
CA2645566A1 (en) | 2007-09-27 |
WO2007109604A3 (en) | 2009-04-09 |
PE20080123A1 (es) | 2008-03-10 |
WO2007109604A2 (en) | 2007-09-27 |
UY30226A1 (es) | 2007-10-31 |
EP2001498A4 (en) | 2013-01-23 |
AU2007226983A1 (en) | 2007-09-27 |
JP2009530415A (ja) | 2009-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059978A1 (es) | Composiciones farmaceuticas | |
SG153800A1 (en) | Pharmaceutical compositions | |
ECSP12012011A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
DOP2013000212A (es) | Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion | |
ECSP13012877A (es) | FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS | |
CR10734A (es) | Anticuerpos e inmunoconjugados y sus usos | |
UY30225A1 (es) | Composiciones farmacéuticas | |
DK2137537T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
AR060978A1 (es) | Anticuerpos e inmunoconjugados y sus usos | |
CL2007001996A1 (es) | Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
DK1763673T3 (da) | Anvendelser af gelformuleringer | |
DK1937824T3 (da) | Sammensætninger af tRNA og anvendelser deraf | |
BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
CR20120158A (es) | Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso. | |
HN2007000437A (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
CR20120362A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
HK1142608A1 (en) | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5- | |
BRPI0820260A2 (pt) | Composição anti-helmíntica e uso da composição | |
UY30801A1 (es) | Compuestos calciliticos | |
AR060849A1 (es) | Polimeros cationicos hidrofobicamente modificados y sus composiciones para el cuidado personal | |
BRPI0615630A2 (pt) | composição farmacêutica, e, uso de sertindol | |
ES2647488T4 (es) | Procedimiento de producción de pastillas que contienen AINE, sus composiciones, su uso medicinal | |
UY30570A1 (es) | Derivaods de feniloxianilina | |
UY30129A1 (es) | Composiciones farmaceuticas | |
CL2009000317A1 (es) | Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |